ROSEN, A LONG-TERM AND TRUSTED FIRM, Urges Investors in Regeneron Pharmaceuticals, Inc. to Secure Counsel Ahead of Important Securities Class Action Deadline
New York, NY – ROSEN, a global investor rights law firm, reminds investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) of the important securities class action deadline in the case against the company. The deadline to file a lead plaintiff motion is [Deadline].
On [Date], Regeneron Pharmaceuticals, Inc. announced that it would be recalling certain batches of its Eylea eye injection due to potential contamination issues. The news sent the company’s stock plummeting, with shares falling [Percentage] on the day of the announcement.
ROSEN, a long-term and trusted firm, is investigating the matter and urges investors who purchased Regeneron Pharmaceuticals, Inc. securities between [Time Frame] to [Time Frame] to secure counsel ahead of the important securities class action deadline.
The investigation focuses on whether Regeneron Pharmaceuticals, Inc. and certain of its officers and directors made false and/or misleading statements, and/or failed to disclose material information, in violation of federal securities laws. Specifically, the investigation concerns the company’s failure to disclose the potential contamination issues with its Eylea eye injection, which led to the recall.
ROSEN, a global investor rights law firm, has a long history of successfully representing investors in securities class actions. The firm’s expertise and resources enable it to provide investors with the highest level of representation and advocacy.
If you purchased Regeneron Pharmaceuticals, Inc. securities between [Time Frame] to [Time Frame] and would like to join the investigation, please contact ROSEN at [Contact Information]. You may also contact ROSEN’s Chief Investment Counsel, [Name], at [Email Address] or [Phone Number].
ROSEN is a global investor rights law firm that has successfully represented investors in securities class actions and other complex litigation. The firm’s attorneys are experienced in representing investors in securities class actions and have a proven track record of success in recovering losses for investors.
This press release is not an advertisement or a solicitation, and it is not intended to form the basis for any investment decision.
